Stock Events

Revolution Medicines 

$29.74
15
+$0.69+2.38% Friday 21:00

Statistics

Day High
29.96
Day Low
28.95
52W High
35.6
52W Low
15.44
Volume
670,465
Avg. Volume
1,126,922
Mkt Cap
4.89B
P/E Ratio
-8.98
Dividend Yield
-
Dividend
-

Upcoming

Earnings

26FebExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Next
-1.01
-0.88
-0.76
-0.63
Expected EPS
-0.91
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RVMD. It's not an investment recommendation.

Analyst Ratings

37.88$Average Price Target
The highest estimate is $47.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Health Technology
Pharmaceuticals: Other
Manufacturing
Biological Product (except Diagnostic) Manufacturing
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Show more...
CEO
Mark Goldsmith
Employees
212
Country
US
ISIN
US76155X1000
WKN
000A2PYWG

Listings